Plain-English translation of NCT06853496 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called in patients with advanced colorectal cancer that has spread to other parts of the body and no longer responds to standard treatments. works by blocking a protein that helps cancer cells grow, and it has shown promise in laboratory studies. This is the first time the medication will be given to people, so the main goal is to understand how safe it is and how well patients tolerate it.
Most patients with advanced colorectal cancer eventually stop responding to standard treatments, leaving them with limited options. This medication was developed based on research showing it might be able to slow or stop cancer growth in a new way, offering hope for patients who have run out of conventional options.
You likely qualify if…
You likely don't qualify if…
You would take as a capsule by mouth as part of this study. The trial is designed to enroll about 48 patients total, and researchers will carefully monitor your health, watch for any side effects, and measure how your cancer responds to the treatment. You would likely have regular visits to the clinic for check-ups, blood tests, and imaging scans to assess your progress.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Japan